not deliver the expected therapeutic breakthroughs” (Goldman, 2012). But there is optimism moving forward as well, Ginsburg said, noting that the same article pointed out that “there is now a unique window of opportunity to tackle these challenges” and a key model for doing so is establishing new models of collaboration among industry, academia, patient groups, regulators, and biotech companies.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement